Pacira Pharmaceuticals Inc (PCRX)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Receivables turnover		6.05	6.41	6.24	6.58	6.37	6.92	6.69	6.27	5.62	9.84	7.15	8.29	8.10	9.13	9.28	11.17	8.86	9.25	9.05	8.90
DSO	days	60.32	56.95	58.47	55.46	57.27	52.76	54.58	58.24	64.92	37.08	51.01	44.02	45.06	40.00	39.35	32.68	41.21	39.47	40.32	41.00

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 6.05
= 60.32

To analyze Pacira BioSciences Inc's days of sales outstanding (DSO) trend, we observe that DSO has been relatively stable over the past eight quarters, ranging from 50.84 days to 57.91 days. In Q4 2023, the DSO stands at 57.08 days, which is slightly higher compared to the previous quarter's 53.16 days.

DSO is a measure of how long it takes for a company to collect its accounts receivable. A higher DSO indicates that the company is taking longer to collect payments from customers, which could potentially impact cash flows and working capital management.

While the stability in DSO may suggest consistent collection practices, it's essential for Pacira BioSciences to monitor this metric closely to ensure efficient cash flow management and timely collection of receivables. Any significant deviations from the historical trend should be investigated to identify potential issues in accounts receivable management.